PF-07284892 in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-02-04
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-patient, open label study is to determine the maximum tolerated
dose and/or recommended dose for further study of PF-07284892 as a single agent and in
combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the
pharmacokinetics, safety, and preliminary clinical activity of single agent and each
combination therapy.